Post-translational modification of lysine residues in erythrocyte α-synuclein

α-Synuclein is a protein linked to various synuclein-associated diseases ('synucleinopathies'), including Parkinson's disease, dementia with Lewy Bodies and multiple system atrophy, and is highly expressed in the central nervous system and in erythrocytes. Moreover, α-synuclein-contai...

Full description

Saved in:
Bibliographic Details
Published inJournal of biochemistry (Tokyo) Vol. 173; no. 3; pp. 177 - 184
Main Authors Amagai, Ryosuke, Yoshioka, Sakura, Otomo, Riki, Nagano, Hidekazu, Hashimoto, Naoko, Sakakibara, Ryuji, Tanaka, Tomoaki, Okado-Matsumoto, Ayako
Format Journal Article
LanguageEnglish
Published England 07.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:α-Synuclein is a protein linked to various synuclein-associated diseases ('synucleinopathies'), including Parkinson's disease, dementia with Lewy Bodies and multiple system atrophy, and is highly expressed in the central nervous system and in erythrocytes. Moreover, α-synuclein-containing erythrocyte-derived extracellular vesicles may be involved in the pathogenesis of synucleinopathies and their progression across the blood-brain barrier. Several post-translational modifications of α-synuclein have been reported in brain inclusions, including S129 phosphorylation, but fewer have been found in erythrocytes. In this study, we analysed the post-translational modifications of erythrocyte α-synuclein using liquid chromatography-mass spectrometry. We found that all lysine residues in the α-synuclein protein could be modified by acetylation, glycation, ubiquitination or SUMOylation but that phosphorylation, nitration and acylation were uncommon minor post-translational modifications in erythrocytes. Since the post-translational modification of lysine residues has been implicated in both membrane association and protein clearance, our findings provide new insight into how synucleinopathies may progress and suggest possible therapeutic strategies designed to target α-synuclein.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-924X
1756-2651
DOI:10.1093/jb/mvac100